Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide

被引:36
|
作者
Jinno, H
Steiner, MG
Mehta, RG
Osborne, MP
Telang, NT
机构
[1] Rockefeller Univ, Div Carcinogenesis & Prevent, Strang Canc Res Lab, New York, NY 10021 USA
[2] Cornell Univ, Coll Med, Dept Otolaryngol, New York, NY USA
[3] Cornell Univ, Coll Med, Dept Surg, New York, NY USA
[4] Univ Illinois, Coll Med, Dept Surg Oncol, Chicago, IL USA
关键词
D O I
10.1093/carcin/20.2.229
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epithelial cells from non-cancerous mammary tissue in response to exposure to chemical carcinogens or transfection with oncogenes exhibit hyperproliferation and hyperplasia prior to the development of cancer. Aberrant proliferation may, therefore, represent a modifiable early occurring preneoplastic event that is susceptible to chemoprevention of carcinogenesis. The synthetic retinoid N-(4-hydroxyphenyl)retinamide (HPR), has exhibited preventive efficacy in several in vitro and in vivo breast cancer models, and represents a promising chemopreventive compound for clinical trials. Clinically relevant biochemical and cellular mechanisms responsible for the chemopreventive effects of HPR, however, are not fully understood. Experiments were performed on preneoplastic human mammary epithelial 184-B5/HER cells derived from reduction mammoplasty and initiated for tumorigenic transformation by overexpression of HER-2/neu oncogene, to examine whether HPR inhibits aberrant proliferation of these cells and to identify the possible mechanism(s) responsible for the inhibitory effects of HPR, Continuous 7-day treatment with HPR produced a dose-dependent, reversible growth inhibition, Long-term (21 day) treatment of 184-B5/HER cells with HPR inhibited anchorage-dependent colony formation by similar to 80% (P < 0.01) relative to that observed in the solvent control, A 24 h treatment with cytostatic 400 nM HPR produced a 25% increase (P = 0.01) in G(0)/G(1) phase, and a 36% decrease (P = 0.01) in S phase of the cell cycle. HPR treatment also induced a 10-fold increase (P = 0.02) in the sub-Go (apoptotic) peak that was down-regulated in the presence of the antioxidant N-acetyl-L-cysteine, Treatment with HPR resulted in a 30% reduction of cellular immunoreactivity to tyrosine kinase, whereas immunoreactivity to p185(HER) remained essentially unaltered. HPR exposure resulted in time-dependent increase in cellular metabolism of the retinoid as evidenced by increased formation of the inert metabolite N-(4-methoxyphenyl) retinamide (MPR) and progressive increase in apoptosis, Thus, HPR-induced inhibition of aberrant proliferation may be caused, in part, by its ability to inhibit HER-2/neu-mediated proliferative signal transduction, retard cell cycle progression and upregulate cellular apoptosis.
引用
收藏
页码:229 / 236
页数:8
相关论文
共 50 条
  • [1] Induction of apoptosis by N-(4-hydroxyphenyl)retinamide in glioma cells
    Saitoh, Y
    Goto, T
    Puduvalli, VK
    Murakami, M
    Kochi, M
    Levin, VA
    Kyritsis, AP
    Ushio, Y
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1999, 15 (03) : 499 - 504
  • [2] Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells
    Wang, TTY
    Phang, JM
    CANCER LETTERS, 1996, 107 (01) : 65 - 71
  • [3] N-(4-HYDROXYPHENYL)RETINAMIDE - A POTENT INDUCER OF APOPTOSIS IN HUMAN NEUROBLASTOMA-CELLS
    MARIOTTI, A
    MARCORA, E
    BUNONE, G
    COSTA, A
    VERONESI, U
    PIEROTTI, MA
    DELLAVALLE, G
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (16) : 1245 - 1247
  • [4] N-(4-hydroxyphenyl)retinamide induces growth arrest and apoptosis in HTLV-I-transformed cells
    N Darwiche
    A Hatoum
    G Dbaibo
    H Kadara
    R Nasr
    G Abou-Lteif
    R Bazzi
    O Hermine
    H de Thé
    Ali Bazarbachi
    Leukemia, 2004, 18 : 607 - 615
  • [5] N-(4-hydroxyphenyl)retinamide induces growth arrest and apoptosis in HTLV-I-transformed cells
    Darwiche, N
    Hatoum, A
    Dbaibo, G
    Kadara, H
    Nasr, R
    Abou-Lteif, G
    Bazzi, R
    Hermine, O
    de Thé, H
    Bazarbachi, A
    LEUKEMIA, 2004, 18 (03) : 607 - 615
  • [6] ENHANCED INHIBITION OF MAMMARY CARCINOGENESIS BY COMBINED TREATMENT WITH N-(4-HYDROXYPHENYL)RETINAMIDE AND OVARIECTOMY
    MCCORMICK, DL
    MEHTA, RG
    THOMPSON, CA
    DINGER, N
    CALDWELL, JA
    MOON, RC
    CANCER RESEARCH, 1982, 42 (02) : 508 - 512
  • [7] Differentiation of human retinal pigment epithelial cells into neuronal phenotype by N-(4-hydroxyphenyl)retinamide
    Chen, SY
    Samuel, W
    Fariss, RN
    Duncan, T
    Kutty, RK
    Wiggert, B
    JOURNAL OF NEUROCHEMISTRY, 2003, 84 (05) : 972 - 981
  • [8] N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-β and induction of apoptosis in human breast cancer cells
    Herbert, BS
    Sanders, BG
    Kline, K
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 1999, 34 (02): : 121 - 132
  • [9] RESTORATION OF APOPTOSIS IN HUMAN PROSTATE CELLS BY TREATMENT WITH N-(4-HYDROXYPHENYL) RETINAMIDE (4-HPR)
    HSIEH, TC
    NG, CY
    MALLOUH, C
    WU, JM
    FASEB JOURNAL, 1995, 9 (06): : A1379 - A1379
  • [10] Cyclooxygenase-2 is essential for HER2/neu to suppress N-(4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells
    Simeone, AM
    Li, YJ
    Broemeling, LD
    Johnson, MM
    Tuna, M
    Tari, AM
    CANCER RESEARCH, 2004, 64 (04) : 1224 - 1228